Date: 2012-07-19
Type of information: Licensing agreement
Compound: near-infrared dye-labelled peptides
Company: Cambridge Research Biochemicals (UK) LI-COR Biosciences (USA)
Therapeutic area:
Type agreement: licensing
development
production
manufacturing
commercialisation
Action mechanism:
Disease:
Details: Cambridge Research Biochemicals has signed a non-exclusive license with LI-COR Biosciences (LI-COR) to develop, manufacture and sell IRDye® and IRDye® QC-1 near-infrared dye-labelled peptides for research use only. CRB is a world leader in providing dye labelled products to researchers. The partnership with LI-COR will enable the company to provide dye labelled peptides, which are unique in the field of fluorescence imaging applications. LI-COR has been developing high-quality near-infrared technology for the life science research community for more than twenty years. LI-COR products support many applications, including quantitative Western blot detection, In-Cell WesternT assays, EMSAs, FLISA, protein assays, florescence microscopy, tissue sections and in-vivo imaging. By partnering both companies are now able to combine their knowledge and expertise in the dye labelled market to offer customers access to the best choice of dye labelled peptides for research purposes.
Financial terms:
Latest news:
